Fact CheckerSign in

NCT04603404Recruiting

Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF

Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Heart Failure With Preserved Ejection Fraction (HFpEF).

Source: ClinicalTrials.gov · Last updated 8 Nov 2022 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.

Status (registry)
Recruiting
Study type
Observational
Enrollment
430 (estimated)
First submitted
14 Oct 2020
Start date
1 Jan 2019
Primary completion date
Dec 2025
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
NCT number
NCT04603404

What you commit to

  • Study type: Observational
  • Planned participants: 430
  • From 1 Jan 2019 to the primary completion date, Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;
  • Severe arrhythmia;
  • Severe primary cardiac valvular disease;
  • Restrictive pericardial disease;

Other

  • Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.
  • Refuse to participate in the study.

Who the study is looking for

  • left ventricular ejection fraction (LVEF)≥50%;
  • N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml;
  • symptoms and syndromes of heart failure;
  • At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).

Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Fuwai Hospital
Coordinator of this site? Confirm its status
BeijingChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.